BridgeMD
Compares treatment options for Fertility Issues
Official title A Multicenter Prospective Randomized Controlled Clinical Trial Comparing Constant (5%) Versus Sequential (5%-2%) Oxygen Concentration Embryo Culture Protocols in Assisted Reproductive Technology
ClinicalTrials.gov ID: NCT07050537
What this study is testing
- What it's testing
- To evaluate whether there were significant differences in the effects of constant (5%) versus sequential (5%-2%) oxygen concentration protocols in embryo culture on term live birth rates. This study will be conducted in five centers including the Clinical Center of Reproductive Medicine, First Affiliated Hospital of Nanjing Medical Universit.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 20 to 40, women only
You may be able to join if
- Female: age ≥20 and ≤40 years, male: age ≥20 and ≤50 years;
- Proposed 1st or 2nd cycle of IVF or ICSI fertilization;
- ≥ 4 transferable embryos at oocyte stage.
You likely can't join if
- Diagnosis of abnormal uterine cavity morphology (confirmed by 3D ultrasound or hysteroscopy), including uterine malformations (mediastinal uterus...
- Patients who are proposed to undergo IVM;
- Patients who are proposed to undergo PGD/ PGS;
- Patients with untreated severe hydrosalpinx (confirmed by ultrasound or HSG);
- Patients with a history of recurrent miscarriage (2 or more previous pregnancy losses, excluding biochemical pregnancies);
- Patients who plan to freeze whole embryos and are unable to complete a single embryo transfer within six months;
See the full eligibility criteria
- Female: age ≥20 and ≤40 years, male: age ≥20 and ≤50 years;
- Proposed 1st or 2nd cycle of IVF or ICSI fertilization;
- ≥ 4 transferable embryos at oocyte stage.
- Diagnosis of abnormal uterine cavity morphology (confirmed by 3D ultrasound or hysteroscopy), including uterine malformations (mediastinal uterus, unicornuate uterus, bicornuate uterus), submucosal uterine fibroids, or...
- Patients who are proposed to undergo IVM;
- Patients who are proposed to undergo PGD/ PGS;
- Patients with untreated severe hydrosalpinx (confirmed by ultrasound or HSG);
- Patients with a history of recurrent miscarriage (2 or more previous pregnancy losses, excluding biochemical pregnancies);
- Patients who plan to freeze whole embryos and are unable to complete a single embryo transfer within six months;
- Patients with contraindications to assisted reproductive technology and pregnancy, or suffering from diseases that have a definite effect on pregnancy: including uncontrolled hypertension, heart disease with definite...
The study team makes the final eligibility decision.
Where it's taking place
- Zhengzhou, Henan, China
- Changzhou, Jiangsu, China
- Nanjing, Jiangsu, China
- Suzhou, Jiangsu, China
- Xi’an, Shanxi, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 20 years to 40 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Zhengzhou, Henan, China; Changzhou, Jiangsu, China; Nanjing, Jiangsu, China; Suzhou, Jiangsu, China; Xi’an, Shanxi, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.